Intec Pharma Stock Forecast, Price & News

Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

Is Intec Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intec Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NTEC, but not buy additional shares or sell existing shares.
View analyst ratings for Intec Pharma or view top-rated stocks.

What stocks does MarketBeat like better than Intec Pharma?

Wall Street analysts have given Intec Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intec Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) released its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share for the quarter, missing the consensus estimate of ($3.48) by $0.36.
View Intec Pharma's earnings history.

When did Intec Pharma's stock split? How did Intec Pharma's stock split work?

Intec Pharma's stock reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of Intec Pharma stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for NTEC?

3 analysts have issued 12 month price objectives for Intec Pharma's shares. Their forecasts range from $52.00 to $52.00. On average, they anticipate Intec Pharma's stock price to reach $52.00 in the next twelve months.
View analysts' price targets for Intec Pharma or view top-rated stocks among Wall Street analysts.

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the following people:

• Jeffrey A. Meckler, Vice Chairman & Chief Executive Officer
• Nir Sassi, President & Chief Financial Officer
• Michael James Newman, Director & Chief Scientific Officer
• Anna Hotovely-Salomon, Director-Clinical Affairs
• Walt A. Linscott, Chief Business Officer

Who are some of Intec Pharma's key competitors?

Some companies that are related to Intec Pharma include Lexaria Bioscience (LEXX), Timber Pharmaceuticals (TMBR), Teligent (TLGT), Histogen (HSTO), Can-Fite BioPharma (CANF), AzurRx BioPharma (AZRX), Integrated BioPharma (INBP), China Health Industries (CHHE), PainReform (PRFX), Guardion Health Sciences (GHSI), MusclePharm (MSLP), NovaBay Pharmaceuticals (NBY), Trevi Therapeutics (TRVI), First Wave BioPharma (FWBI) and Benitec Biopharma (BNTC).
View all of NTEC's competitors.

What other stocks do shareholders of Intec Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), (CGC), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST).

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering (IPO) on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (3.88%) and Morgan Stanley (3.88%). Company insiders that own Intec Pharma stock include Issac Silberman and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Intec Pharma.

Which institutional investors are buying Intec Pharma stock?

NTEC stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Intec Pharma or or view top insider-buying stocks.

How much money does Intec Pharma make?

Intec Pharma has a market capitalization of $0.00. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.

How many employees does Intec Pharma have?

Intec Pharma employs 40 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

Where are Intec Pharma's headquarters?

Intec Pharma is headquartered at 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at (722) 586-4657 or via email at [email protected].